Bnp Paribas Asset Management Holding S.A. Crispr Therapeutics Ag Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 761 shares of CRSP stock, worth $41,855. This represents 0.0% of its overall portfolio holdings.
Number of Shares
761Holding current value
$41,855% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
498Shares Held
65.8MCall Options Held
2.16MPut Options Held
2.1M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$560 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$334 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$209 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$153 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$140 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.29B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....